Diagnostics

Learn how our advanced genetic tests are revolutionizing health

Drug Response Panel

The Drug Response Panel is a comprehensive next-generation sequencing (NGS) panel that can be used to determine a patient’s response to various drugs based on their genotype, which can assist in determining optimal dosing and reducing adverse events.

The Drug Response Panel covers hundreds of the most commonly prescribed drugs across of a large cross section of therapeutic areas. Genetic factors account for 20% to 95% of variability in response to individual drugs (Kalow et al, 1998) and 10% to 20% of adverse drug reactions may be related to genetic factors (Ingelman-Sundberg, 2004). Therefore, pharmacogenomic testing can reduce adverse drug reactions, help optimize dosing, and assist in selecting the most effective medication.

Variant Selection

This test includes and reports only variant/drug relationships for which there is strong evidence of drug response being affected by a patient’s genotype. Therefore, this test only reports variant/drug relationships that have Clinical Pharmacogenetics Implementation Consortium (CPIC) evidence level of an A or B, a PharmGKB evidence level of 1 or 2, or are referenced in the FDA drug label.

Included Drugs

The Drug Response Panel covers pharmacogenomics of drugs related to the following therapeutic areas (please see the Drug Response Gene List Sheet for a full list of assayed drugs):

Cardiology Psychiatry Oncology Pain Management Neurology
Immunology Gastroenterology Respiratory Infectious Disease Others

 

Methodology and Analytical Sensitivity

Next-generation sequencing technology is used to test clinically relevant portions of each gene, including coding exons, adjacent flanking bases, and selected introns/noncoding variants. Pathogenic and likely pathogenic variants are confirmed by orthogonal methods. Copy number variants, including intragenic deletions and duplications are detected to a resolution of a single exon. Analytical sensitivity and specificity of the assay is >99%.

Indications for Testing

  • Assessment of risk of altered metabolism of drugs based on genotype

Included Genes (85)

ABCB1 CETP CYP3A4 FDPS HLA-DRB1 MC4R SLC28A3 UGT1A4
ABCG2 CFTR CYP3A5 G6PD HMGCR MTHFR SLC6A4 UGT2B15
ACE COMT CYP4F2 GRIK4 HTR1A NAT2 SLCO1B1 UMPS
ADD1 COQ2 DPYD GSTM1 HTR2A NQO1 TANC1 VDR
ADORA2A CRHR1 DRD2 GSTP1 HTR2C NT5C2 TCF7L2 VKORC1
ANKK1 CRHR2 DYNC2H1 HAS3 IFNL3 NUDT15 TNF XPC
APOE CYP2B6 EPHX1 HLA-A ITPA OPRM1 TP53 XRCC1
ATIC CYP2C19 ERCC1 HLA-B KCNIP4 PTGS1 TPMT
CBR3 CYP2C8 F2 HLA-C KIF6 PTPGFR TXNRD2
CCHCR1 CYP2C9 F5 HLA-DPB1 LPA SCN1A TYMS
CES1 CYP2D6 FASTKD3,MTRR HLA-DQA1 LTC4S SEMA3C UGT1A1

 

References

  1. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193-200.
  2. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–289.